Astellas Pharma Inc. (4503.T) Stock

4503.T logo

Astellas Pharma Inc.

4503.TJapan
Healthcare

Company profile

Astellas Pharma reported revenue of 1.91 trillion JPY for fiscal year 2025, up 19.2% from fiscal year 2024, and net income of 50.75 billion JPY. That is a net profit margin of 2.7% for fiscal year 2025. USA was its largest region in fiscal year 2025, with 46% of revenue. Our analysis of its filings shows revenue growing from 1.52 trillion JPY in fiscal year 2023 to 1.91 trillion JPY in fiscal year 2025, 12.2% a year on average. Astellas Pharma reports about 14,099 full-time employees.

What stands out

  • Net income more than doubled in fiscal year 2025, from 17.05 billion JPY in fiscal year 2024.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended March 31, 2025.

About Astellas Pharma Inc.

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.

Largest shareholders

  • BlackRock Fund Advisors3.97%
  • Amova Asset Management Co., Ltd.3.16%
  • Nippon Life Insurance Co.2.85%
  • BlackRock Japan Co. Ltd.2.24%
  • Astellas Pharma Director Incentive Plan0.98%

Share of the company, as of September 25, 2026

Leadership

  • Naoki Okamura BSc — President, CEO & Representative Director, 63
  • Nobuaki Tanaka — President of Japan Commercial & Senior Corporate Executive
  • Atsushi Kitamura — Chief Financial Officer
  • Katsuyoshi Sugita — Executive VP, Chief People Officer & Representative Director, 58
  • Yoshitsugu Shitaka Ph.D. — Chief Scientific Officer & Senior Managing Executive Officer

How much revenue does Astellas Pharma make?

Astellas Pharma reported 1.91 trillion JPY in revenue for fiscal year 2025, up 19.2% from 1.60 trillion JPY in fiscal year 2024.

Where does Astellas Pharma make most of its revenue?

USA: 46% of revenue by region in fiscal year 2025, followed by Others (40%).

What companies are similar to Astellas Pharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Chugai Pharmaceutical Co., Ltd. (4519.T), Otsuka Holdings Co., Ltd. (4578.T), Daiichi Sankyo Company, Limited (4568.T), Eisai Co., Ltd. (4523.T).

Has Astellas Pharma made a profit in recent years?

Net income by fiscal year: FY2021, 120.59 billion JPY; FY2022, 124.09 billion JPY; FY2023, 98.71 billion JPY; FY2024, 17.05 billion JPY; FY2025, 50.75 billion JPY. It was profitable in each of these years.

How has Astellas Pharma's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 1.25 trillion JPY; FY2022, 1.30 trillion JPY; FY2023, 1.52 trillion JPY; FY2024, 1.60 trillion JPY; FY2025, 1.91 trillion JPY.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees14,099
FoundedApr 1, 2005
IPO DateMay 16, 1949
IPO StatusPublic
HeadquartersChuo, Japan
FoundersErik Karrer
ExchangeTokyo
TimezoneAsia/Tokyo (JST)

Contact & Links

Address
2-5-1, Nihonbashi-Honcho, Chuo, 103-8411
Phone
81 3 3244 3000
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Astellas Pharma Inc. (4503.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4503.T

LinkedInLinkedInXXYouTubeYouTube